The Promise of Nutrient-Derived Bioactive Compounds and Dietary Components to Ameliorate Symptoms of Chemotherapy-Related Cognitive Impairment in Breast Cancer Survivors.
Nagi B KumarPublished in: Current treatment options in oncology (2021)
One of the most burdensome symptoms reported by breast cancer patients is chemotherapy-related neurocognitive impairment. It is estimated that of the 11 million cancer survivors in the USA, 22% of them are breast cancer patients. The National Cancer Institute classified chemotherapy-related cognitive impairment (CRCI) as one of the most debilitating sequelae of cancer therapy, limiting this patient population from recommencing their lives prior to the diagnosis of breast cancer. Currently, there are no strategies that are established to prevent, mitigate, or treat CRCI. In addition to surviving cancer, quality of life is critical to cancer survivors. Based on the multiple and complex biological and psychosocial etiology, the varying manifestation and extent of cognitive decline documented in breast cancer survivors, possibly attributed to varying combinations of chemotherapy and dose and duration of therapy, multimodal interventions combining promising nutrient-derived bioactive compounds with antioxidant and anti-inflammatory properties, in addition to structured cognitive training and exercise regimens, can work synergistically to reduce inflammation and oxidative stress with significant improvement in cognitive function resulting in improvements in quality of life of breast cancer survivors.
Keyphrases
- oxidative stress
- cognitive impairment
- cognitive decline
- locally advanced
- anti inflammatory
- young adults
- physical activity
- mild cognitive impairment
- dna damage
- childhood cancer
- squamous cell carcinoma
- drug delivery
- stem cells
- mental health
- chemotherapy induced
- case report
- papillary thyroid
- rectal cancer
- radiation therapy
- bone marrow
- big data
- depressive symptoms
- bipolar disorder
- heat stress